Sydney, Australia - 23 May 2025 - Merck, a leading science and technology company, today announced it is joining forces with non-profit research organisation Omico. Under a new initiative Merck will work with Omico to leverage the groundbreaking national population screening and clinical trial network, helping patients more quickly connect with company sponsored cancer trials.

Sydney, Australia - 10 April 2025 - Icon Cancer Centre and Omico have announced an important collaboration aimed at expanding access to precision oncology and clinical trials for Australian cancer patients. By leveraging Icon’s extensive national network of cancer centres and Omico’s expertise in molecular profiling and targeted therapy trials, this partnership is set to improve access to cancer screening and evolve Australia’s cancer care landscape. 

Sydney, Australia – 6 February 2025 - Omico welcomes the Federal Government’s significant $143.4 million investment in world-leading precision oncology programs — the Zero Childhood Cancer Program and PrOSPeCT—supporting children and adults diagnosed with challenging cancers. PrOSPeCT has been instrumental in providing Australians with advanced, incurable and poor prognosis cancer diagnoses the ability to receive precision oncology and is a critical initiative advancing cancer care in this country.

Sydney, Australia – 5 February 2025 - Omico is excited to announce the launch of the MoST/CASP-SARC Initiative, a pivotal new research project aimed at transforming treatment options for sarcoma—one of the most challenging and aggressive cancers. 

Sydney, Australia - 11 February 2025 – Omico is taking another major step in helping Australians diagnosed with challenging cancers, along with their families and carers, to better understand genomics and precision oncology – critical components of modern cancer care. With the launch of its first-of-its-kind podcast series, Cancer Meets its Match, Omico is making this complex science more accessible.

Sydney, Australia - 4 February 2025 - Omico, the not-for-profit genomics pioneer, has formally proposed a ‘first of its kind,’ transformative model that transitions groundbreaking ‘state of the art’ cancer treatments into affordable, routine clinical care for Australians diagnosed with rare and challenging cancers. The Precision Oncology Health System Incubator (PrO-HSI) sets out a strategic investment pathway with multi-sector funding using established policy and infrastructure frameworks, to integrate advanced therapies into contemporary cancer care without overwhelming public resources amid a diminishing taxpayer base and ageing population.

Sydney, Australia - 27 November 2024 -Omico will take another key step forward in 2025 to educate those diagnosed with challenging cancers, their families and carers, on the significant technological advances and innovative treatment options now available through genomics.

Sydney, Australia - 27 November 2024 - At Omico, collaboration and data-driven insights are core to our mission to advance cancer care. Through the ASPiRATION study*, we have partnered with the Thoracic Oncology Group of Australasia (TOGA), NHMRC Clinical Trials Centre (CTC), University of Sydney, and industry partners, supported by the Australian Government’s Medical Research Future Fund (MRFF) and Roche Products  Pty. Limited. Together, we are exploring the impact of comprehensive genomic profiling (CGP) and precision medicine for metastatic lung cancer—a disease with a challenging five-year survival rate of only 17%.

Sydney, Australia - 22 November 2024 - Professor David Thomas, Founder of not-for-profit genomics organisation, Omico, and Director, Centre of Molecular Oncology, UNSW has been awarded NSW’s highest accolade for cancer research at the NSW Premier’s Awards for Outstanding Cancer Research.

Sydney, Australia - 1 October 2024 - National, not for profit genomic pioneer, Omico, welcomes the formal announcement of a unique collaboration with Tessellate BIO and CMRI (Children’s Medical Research Institute) which focusses on advancing the understanding of alternative lengthening of telomeres (ALT), a mechanism present in cancer cells, and accelerating the development of precision medicines to target it.

Sydney, Australia – August 21, 2024 - This week, not-for- profit genomics pioneer, Omico, commences a first-of-its kind national educational initiative to provide Australians with advanced, incurable or poor prognosis cancers an increased understanding of the power of comprehensive genomic profiling (CGP) and precision oncology as a genuine component of an advanced cancer management plan.

Sydney, Australia – 26 June 2024 - Addressing the National Press Club on Rare Cancers Awareness Day (26 June), Prof Thomas will call for a bolder approach to harnessing rapid advances in cancer innovation known as ‘precision oncology’. For Australians with the challenging diagnosis of rare, advanced or incurable cancers he wants the words ‘it’s time to get your affairs in order and prepare your family’ to be replaced with an immediate directive to the genomics tools now available – genomic profiling of the cancer and matching to precision medicines.

Sydney, Australia – 6 June 2024 - Hear from the 'Godfather' of rare cancer science and precision oncology, Professor David Thomas, announcing the latest groundbreaking cancer research outcomes in the country on Wednesday 26th June, coinciding with Rare Cancers Awareness Day and the National Health Journalism Awards.

Sydney, Australia – 5 June 2024 - 5000 Australians with toughest cancers referred to PrOSPeCT for free comprehensive genomic profiling. The nation’s largest cancer genomics initiative PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) has reached a major milestone this month with over 5,000 Australians, diagnosed with hard-to-treat cancers with very limited treatment options, receiving referrals for free comprehensive genomic profiling (CGP) of their cancer.

Sydney, Australia – 19 April 2024 - PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) is our landmark precision oncology initiative, enabled by public-private funding and partnerships totalling over $185M, including $61.2M grant funding from the Australian Government.

Sydney, Australia – 18 April 2024 - Omico recognises that patient advocacy organisations are experts in understanding the patient, family and community experience with cancer, tailoring information, and support, and advocating for equity of access to the latest advances in diagnosis, treatment and care.

Sydney, Australia – 12 April 2024 - With respect to our landmark initiative PrOSPeCT, supporting Omico on this journey are two key partners, Quantium and Australia's largest supercomputing centre, National Computational Infrastructure (NCI Australia). Quantium is well known  in the data science and artificial intelligence space and assists by providing its advanced analytical firepower. In parallel, NCI provides a secure and protected environment to house data from PrOSPeCT and a powerful platform for sharing data to enable the analysis of large quantities of genomic information, effectively bringing precision medicine to real-world data.

Sydney, Australia – 18 April 2024 - Omico is dedicated to advancing cancer treatment and care by establishing and supporting a network of clinical trial sites. Coordinated by Lucille Sebastian, the Omico National Clinical Trials Network (ONCTN), aims to broaden treatment options to patients whilst improving equitable access to clinical trials. This endeavour involves collaboration with various stakeholders including clinical trial units, clinicians, patients, and pharmaceutical companies.

Sydney, Australia – 12 March 2024 – Omico, the pioneering, not-for-profit, national organisation accelerating access to precision oncology in Australia, proudly announces Ian Black as its new full-time Chief Executive Officer (CEO), effective 2 April 2024. Mr Black joins Professor David Thomas, Omico’s founder, who will continue to play a vital role within the organisation. This transition signifies a pivotal moment in Omico's journey, a necessary evolution of its organisational structure to effectively manage current priorities, ongoing growth and ensure longterm sustainability.

Sydney, Australia – 27 July 2023 - Pioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers

Sydney, Australia – 17 March 2023 - As of March 2023, we have screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study.

Sydney, Australia – 20 January 2023 - Research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney has generated the first comprehensive genetic map of sarcomas, identifying several new important genes that when inherited can cause this deadly cancer. The research has wide implications for people living with sarcoma and their families – allowing detection of the cancer earlier and potentially improving survival for patients.

Sydney, Australia – 16 November 2022 - The Australian Government’s Federal Budget announcement brings new hope to Australian families carrying gene variants with an extreme risk of cancer (Li-Fraumeni syndrome, known as LFS), with a four year $1.9M commitment to fund whole-body magnetic resonance imaging (MRI) under the Medicare Benefits Schedule (MBS).

Sydney, Australia – 25 October 2022 - We are so pleased that 5,000 Australian cancer patients have accessed genomic technology via our Molecular Screening and Therapeutics (MoST) study.

Sydney, Australia – 24 October 2022 - Our team David Thomas and Mandy Ballinger has received a collaborative grant through the U.S. National Cancer Institute (NCI)'s Specialized Program of Research Excellence (SPORE).